



**SASM** Society of Anesthesia and Sleep Medicine  
Find and Connect With Us: [Facebook icon] [Twitter icon] [LinkedIn icon]

## Pulmonary Hypertension and Sleep-Disordered Breathing/Obesity in the Perioperative Setting

Stavros G. Memtsoudis, MD, PhD, MBA, FCCP  
 Clinical Professor of Anesthesiology and Health Policy and Research  
 Weill Cornell Medical College  
 Attending Anesthesiologist and Senior Scientist  
 Director Critical Care Services  
 Hospital For Special Surgery


---

---

---

---

---

---

---

---

## Disclosure

- Owner: SGM Consulting, LLC
- Co-Owner, COO: FC Monmouth, LLC, FC Monmouth Academy, LLC
- Consultant: Sandoz, Teikoku
- Patent: Multicatheter Infusion System. U.S. Patent No. US-2017-0361063

---

---

---

---

---

---

---

---

## Objectives

- Definition
- Epidemiology
- Perioperative Outcomes in Patients with PHTN
- Link Between OSA, Obesity and PHTN
- Effect of Surgery on PHTN
- Potential Efficacy of Disease Specific Interventions
- Conclusions

---

---

---

---

---

---

---

---

# Definition and Classification

---

---

---

---

---

---

---

---

## Definition

- PHTN = mean PAP at or above 25mmHG at rest or 30mmHG with exercise
  - Mild = 25-40mmHg
  - Moderate = 41-55mmHg
  - Severe = > 55mmHg

Badesch DB, et al. J Am Coll Cardiol 2009; 54:S55-66.

---

---

---

---

---

---

---

---

**BOX 1: Updated Clinical Classification of Pulmonary Hypertension, Paris Point score**

**1. Pulmonary arterial hypertension (PAH)**

- 1.1. Idiopathic PAH (IPAH)
- 1.2. Heritable PAH
  - 1.2.1. BMPR2
  - 1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
  - 1.2.3. Unknown
- 1.3. Drug and toxin-induced
- 1.4. Associated with (A)PAH
  - 1.4.1. Connective tissue disease
  - 1.4.2. HIV infection
  - 1.4.3. Portal hypertension
  - 1.4.4. Congenital heart diseases
  - 1.4.5. Scleroderma
  - 1.4.6. Chronic hemolytic anemia
- 1.5. Persistent pulmonary hypertension of the newborn (PPHN)

<sup>1</sup> Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)

**2. Pulmonary hypertension owing to left heart diseases**

- 2.1. Systolic dysfunction
- 2.2. Diastolic dysfunction
- 2.3. Valvular disease

**3. Pulmonary hypertension owing to lung diseases and/or hypoxia**

- 3.1. Chronic obstructive pulmonary disease
- 3.2. Interstitial lung disease
- 3.4. Sleep-disordered breathing
- 3.5. Chronic hypersplenism
- 3.6. Chronic exposure to high altitude
- 3.7. Developmental abnormalities

**4. Chronic thromboembolic pulmonary hypertension (CTEPH)**

**5. Miscellaneous**

- 5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
- 5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis
- 5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
- 5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis

Simonneau G, et al. J Am Coll Cardiol 2009;54: S43-54.

---

---

---

---

---

---

---

---

# Epidemiology

---

---

---

---

---

---

---

---

### The link between OSA, Obesity and PHTN

- Risk Factors include advanced age, OSA and obesity
- All very prevalent in orthopedic pts
- Prevalence
  - 6% of pts over 50 years
  - 5% of pts with BMI over 30kg/m<sup>2</sup>
  - 17-52% of OSA pts
  - Among those with PHTN 45% have OSA
  - Estimates suggest that 2.5Million pts with OSA have PHTN in US alone

McQuillan BM, et al. Circulation 2001;104:2797-2802  
Bady G, Thorax 2000;55:934-939  
Krieger J, Chest 1989;96:729-737  
Chaouat A, Chest 1996;109:380-386  
Sajkov D et al. Am J Respir Crit Care Med 1999;159:1518-1526  
Ulrich S, et al. Chest 2008;133:1375-1380

---

---

---

---

---

---

---

---

# Pathophysiology

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

Sleep Health  
DOI: 10.1007/s11325-018-0566-1  
ORIGINAL ARTICLE

**Mal-effects of obstructive sleep apnea on the heart**

Song-qing Yang · Lei-Bi Han · Xiao-tu Dong · Chun-yang Wang · Huan-Niu · Fan Liu · Jing-hua Wang · Ping-ping He · Sheng-min Liu · Ming-xiao Li

**Table 5** Changes of pulmonary artery systolic pressure in OSA patients

Group	Number of patients, N	Pulmonary artery systolic pressure (mmHg)
Control	35	22±5
Mild	33	28±6
Moderate	47	38±6*
Severe	41	55±11**

\*P<0.05 (vs. mild); \*\*P<0.01 (vs. moderate)

**Frequency and Impact of Pulmonary Hypertension in Patients With Obstructive Sleep Apnea Syndrome**

Omar A. Mhazir, MD<sup>1,2,3,4,5</sup>, Hanna Riccio, MD<sup>6\*</sup>, Roop Kaur, MD<sup>7</sup>, Jeff Hammel, MD<sup>8</sup>, Mary Morrow, MD<sup>9</sup>, Kevin McCarthy, PhD<sup>10,11</sup>, Joseph A. Golish, MD<sup>12,13</sup>, and James K. Stoller, MD<sup>14</sup>

Characteristic	All (n = 83)	Pulmonary Hypertension		p Value*
		No (n = 25)	Yes (n = 58)	
Age (years)	56.7 ± 13	58.4 ± 13.6	55.9 ± 13	0.38
Gender				0.01
Men	48 (57.8%)	20 (42)	28 (58)	
Women	35 (42.2%)	5 (14)	30 (60)	
Body mass index (kg/m <sup>2</sup> )	34.3 ± 8.8	31.2 ± 6.9	35.6 ± 9.3	0.026
Hemoglobin (g/dL)	12.3 ± 1.9	12.3 ± 2.1	12.3 ± 1.9	0.76
Apnea-hypopnea index (events/hour of sleep)	30.8 ± 22.8	34.6 ± 27.8	29.1 ± 21.9	0.52
OSA severity by apnea-hypopnea index				0.42
Mild	39 (47%)	11 (28)	28 (72)	
Moderate		7 (25)	21 (75)	
Severe		7 (44)	9 (50)	
Nocturnal oxygen desaturation				0.13
<10% of total sleep time	15 (64%)	17 (35)	31 (65)	
≥10% of total sleep time	27 (36%)	5 (18)	22 (82)	
Not reported	8 (10%)	3 (12)	5 (23)	
Duration of nocturnal desaturation (% total sleep time)	16.7 ± 25.4	7.4 ± 12.1	20.5 ± 28.5	<0.018
Mean pulmonary arterial pressure (mm Hg)	33.8 ± 13.6	18.7 ± 3.5	40.3 ± 11	<0.001
Cardiac index (l/min/m <sup>2</sup> )	2.4 ± 1.1	2.65 ± 1.6	2.3 ± 0.9	0.16
Cardiac index <2	26 (35%)	4 (16%)	22 (80%)	0.09
Pulmonary vascular capacitance (ml/min Hg)	3.0 ± 2.3	4.8 ± 2.9	2.2 ± 1.3	<0.001
Forced vital capacity (% predicted) (n = 31)	68.6 ± 16	72 ± 16	68.8 ± 16	0.082
Forced expiratory volume in 1 s (% predicted) (n = 51)	65.9 ± 17	70 ± 17	64.8 ± 16	0.31
Six-minute walk test (m) (n = 25)	295 ± 136	343 ± 213	285 ± 122	0.5


\*p Value for comparison of patients with and without PH.

70% PTHN

**Perioperative Outcomes**

**Perioperative Mortality in Patients with Pulmonary Hypertension Undergoing Major Joint Replacement**

Stavros G. Memtsoudis, MD, PhD,\* Yan Ma, PhD,† Ya Lin Chiu, MS,† J. Matthias Walz, MD,† Robert Voswinckel, MD,§ and Madhu Mazumdar, PhD†



Anesth Analg. 2010 Nov;111(5):1110-6.

---

---

---

---

---

---

---

---

---

---

**Perioperative Outcomes after Unilateral and Bilateral Total Knee Arthroplasty**

Stavros G. Memtsoudis, M.D., Ph.D.,\* Yan Ma, Ph.D.,† Alejandro Gonzalez Della Valle, M.D.,‡ Madhu Mazumdar, Ph.D.,§ Lida R. Gaber-Baylis, B.A.,|| G. Ronald Michenerle, M.D.,¶ Thomas P. Sculco, M.D.,\*\*

Table 5. Risk Factors for Perioperative Mortality after Total Knee Arthroplasty—Coxworth Model (Model 2)

Comorbidity	Regression Coefficient	Odds Ratio	95% CI	P Value
Alcohol abuse	0.25	1.28	0.57–2.88	0.552
Chronic lung disease	0.18	1.2	0.98–1.47	0.0844
Congestive heart failure*	1.62	5.03	1.14–6.11	< 0.0001
Uncomplicated diabetes mellitus	0.12	1.13	0.92–1.39	0.2475
Complicated diabetes mellitus	0.13	1.13	0.67–1.92	0.643
Liver dysfunction	0.28	1.32	0.55–3.17	0.5281
Coagulopathy*	0.86	2.32	1.87–2.91	< 0.0001
Neurologic disorders*	1.03	2.8	1.5	< 0.0001
Obesity	-0.26	0.77	0.5	< 0.0001
Peripheral vascular disease*	0.4	1.5	1.0	< 0.0001
Renal disease*	1.26	3.56	2.5	< 0.0001
Pulmonary circulatory disease*	2.46	11.75	9.05–15.25	< 0.0001
Disability	0.12	1.12	0.84–1.49	0.4278
Cardiac valvular disorders	0.89	2.43	1.87–3.14	< 0.0001
Electrolyte/acid abnormalities*	1.3	3.67	3.06–4.4	< 0.0001
Melanistic cancer*	1.33	3.76	1.06–13.02	0.0364
Cancer	0.18	1.2	0.54–2.68	0.6535

NIS  
3.4 Million patients 1998-2006  
Pulmonary circulatory disease\* 2.46 11.75 9.05-15.25 < 0.0001  
Anesthesiology 2009; 111:1206-16

---

---

---

---

---

---

---

---

---

---

**Perioperative Insults Worsening PHTN**

---

---

---

---

---

---

---

---

---

---

### Perioperative Insults Worsening PHTN

- Hypoxemia
- Hypercapnia (hypoventilation, CO2 peritoneum)
- Acidosis
- Hypothermia
- Hypervolemia
- Increase in intrathoracic pressure (mechanical ventilation/pneumoperitoneum)
- Insufficient anesthesia and analgesia/sympathetic surges

---

---

---

---

---

---

---

---

### PHTN in Orthopedic Patients Pathophysiology

---

---

---

---

---

---

---

---

### Orthopedic Pathophysiology




Figure 3. Transesophageal echocardiography four-chamber image during reduction of the hip prosthesis. 1 = right atrium; 2 = right ventricle; 3 = left ventricle.

Figure 4. Transesophageal echocardiography four-chamber image during reduction of the hip prosthesis in a patient who had a fatal reaction to the bone cement implantation syndrome. Arrow marks large echogenic material in the right atrium and right ventricle.

Urban et al, Anesth Analg 1996; 82:1225-9

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---



So what do I do?

---

---

---

---

---

---

---

---

**Difficulty diagnosing**

- “Double occult disease” – majority of OSA patients is undiagnosed at time of surgery
- and PHTN is an occult disease
- Technically difficult to do echo in obese patients
- Ortho patients often physically not able to tolerate exercise, i.e. 6 min walk test.

---

---

---


---

---

---

---

---

 European Heart Journal (2009) 30, 2493–2537  
doi:10.1093/eurheartj/ehp297

**ESC/ERS GUIDELINES**

---

**Guidelines for the diagnosis and treatment of pulmonary hypertension**

**The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)**

**Table 3: Clinical findings in patients with pulmonary hypertension (mod. [1]).**

- (I) Dyspnoea (during stress/at rest)/cyanosis
- (II) Fatigue
- (III) Diarrhoea
- (IV) Syncope
- (V) Thoracic pain
- (VI) Palpitations
- (VII) Orthopnoea
- (VIII) Cough
- (IX) Creackiness
- (X) Abdominal tension
- (XI) Peripheral Edema/Asthes
- (XII) Hepatomegaly

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Preoperative Treatment

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

### Impact of Disease Specific Interventions on PHTN in OSA and Obese Patients

---

---

---

---

---

---

---

---

European Heart Journal (2009) 30, 1106–1113  
doi:10.1093/eurheartj/ehp389

**Clinical research**  
Hypertension

**Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure**  
A randomized, controlled cross-over study

Miguel A. Arias<sup>1</sup>, Francisco Garcia-Rio<sup>2\*</sup>, Alberto Alonso-Fernández<sup>3</sup>, Isabel Martínez<sup>4</sup>, and José Vilander<sup>5</sup>

- N=23 OSA patients, 10 PHTN
- 3 months CPAP

PAP (mmHg)

Sham CPAP CPAP

$P < 0.0001$

---

---

---

---

---

---

---

---

**Respiration**

Clinical Investigations  
Daytime Pulmonary Hypertension in Patients with Obstructive Sleep Apnea

The Effect of Continuous Positive Airway Pressure on Pulmonary Hemodynamics  
Alchanatis M<sup>a</sup>, Tourkourhiti G<sup>a</sup>, Kakouras S<sup>b</sup>, Kosmas E<sup>c</sup>, Podaras S<sup>a</sup>, Jordanoglou J.S.<sup>a</sup>

- N=29
- 20% with OSA had PHTN that was clinically mild (mean PAP, 25.6 mm Hg).
- PHTN pts were older and increased BMI
- 6 months of CPAP treatment was associated with reductions in mean PAP in OSA pts with PHTN ( $25.6 \pm 4.0$  to  $19.5 \pm 1.5$  mm Hg) and those without PHTN ( $14.9 \pm 2.2$  to  $11.5 \pm 2.0$  mm Hg).

Alchanatis M, et al Respiration 2001;68:566–572.

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

*Obesity Surgery*, 14, 753–762

**Effect of Bariatric Surgery on Obstructive Sleep Apnea and Hypopnea Syndrome, Electrocardiogram, and Pulmonary Arterial Pressure**

Matilde Valencia-Flores, PhD<sup>1,6</sup>; Arturo Orea, MD<sup>2</sup>; Miguel Herrera, MD, PhD<sup>3</sup>; Victoria Santiago, MS<sup>1</sup>; Verónica Rebolgar, MD<sup>2</sup>; Violeta A. Castaño, MS<sup>1</sup>; Jorge Oseguera, MD<sup>2</sup>; Jorge Pedroza, MD<sup>4</sup>; Jorge Sumano, MS<sup>1</sup>; Montserrat Resendiz, MS<sup>1</sup>; Guillermo García-Ramos, MD<sup>1</sup>

**Pulmonary Artery Pressure**

Before surgery, 28 patients (96.5%) presented pulmonary arterial hypertension (range 31.0–80.5 mmHg). After surgery, it completely resolved in only 4 patients. However, mean SPAP significantly decreased in the group of obese patients in whom OSAHS resolved after surgery from a mean of 61.4±15.8 mmHg to a mean of 42.6±9.2 mmHg. In

---

---

---

---

---

---

---

---

---

---

Anesthetic Care

---

---

---

---

---

---

---

---

---

---



## Summary

- PHTN is common in patients with OSA and obesity.
- The underlying pathophysiology of each disease process may be synergistic and potentially additive in the development of PHTN.
- A high level of suspicion is needed for diagnosis and referral to expert care is advised.
- PHTN is associated with adverse perioperative outcomes.
- PHTN can worsen perioperatively due to a number of mechanisms.
- The treatment of obesity and OSA may reduce the severity of PHTN and potentially cure it.

---

---

---

---

---

---

---

---